Brett Aitken, Publisher of Stansberry Research and Dave Lashmet, Editor of Stansberry Venture Technology recently shared one of the top ideas in their firm’s entire history.
Their urgent message comes at a critical moment.
In only a few weeks, the most significant new advancement in biotechnology is expected to happen. This announcement could send a few specific drugmaker stocks soaring overnight. If you act now, you might receive 1,000% upside.
Read further for everything you need to know about this rare opportunity. It is covered as part of small cap investing newsletter called Stansberry Venture Technology.
Weight Loss Drug Revolution
The groundbreaking medications discussed in Stansberry’s presentation are known as GLP-1 drugs, named for their ability to mimic glucagon-like peptide 1—a hormone that lowers blood sugar, slows digestion, and curbs appetite.
While you may see these drugs as “new” or “unproven,” they actually have a well-established safety record for decades. Their origins trace back to the 1980s when insulin manufacturers first explored them for diabetes and stomach ulcers. Early versions degraded too quickly in the body to be effective—until a remarkable discovery changed everything…
The Gila Monster Connection
A scientist found that a small protein in the venom of the Gila monster, a poisonous lizard, had effects similar to GLP-1 but lasted significantly longer in the body.
The real breakthrough came when researchers realized these diabetes drugs had an unprecedented side effect: They safely and dramatically reduced appetite.
A Historic Breakthrough in Weight Loss
In controlled clinical trials, GLP-1 drugs demonstrated weight loss results of 10% – 20%. To put that into perspective, no previous medication in history has achieved such safe and effective weight loss.
Over 1.1 billion people could benefit from these drugs, potentially making them the most prescribed medications in the world. Currently, the most prescribed drug, Atorvastatin (a cholesterol-lowering medication), is used by 28 million Americans.
For comparison, even the best behavioral interventions—diet, exercise, and lifestyle changes—typically result in only 5% weight loss, which is rarely maintained. GLP-1 drugs are delivering four times better outcomes, with reports of 50-, 70-, and even 100-pound weight loss.
Beyond Weight Loss
These medications have already been approved for treating:
- High blood pressure—affecting half of U.S. adults and contributing to 700,000 deaths per year.
- Diabetes
- Sleep apnea.
And they could soon become some of the most important heart disease treatments in history.
A Game-Changer for Healthcare and the Market
The potential cost savings for the U.S. healthcare system are enormous. The financial opportunity for the companies producing these drugs is unlike anything seen before. Surpassing any previous drug or medical device.
While some companies have already seen significant gains, a major roadblock has held back the full market potential. But that obstacle is about to disappear—unlocking a surge in value unlike anything we’ve seen.
Innovation No One Sees Coming
These drugs are complex and incredibly expensive to produce. As a result, their high retail prices limit patient access.
While pharmaceutical companies are pouring billions into building factories to scale up production, that process takes years. In the meantime, demand far outpaces supply.
Adding to the challenge, these drugs are only available as injections—a dealbreaker for many patients.
But that’s all about to change. Because a safe, effective, and more affordable pill is on the horizon. It’s expected to transform everything.
How To Profit From GLP-1 Revolution?
Dave Lashmet, the Editor of Stansberry Venture Technology published a newly updated report called “How to Profit – and Keep Profiting – From the GLP-1 Revolution.”
I have no doubt that this is the most in-depth and comprehensive research available on this opportunity. It is crafted by an analyst who has tracked every detail from the very beginning, years ahead of the rest of the market.
This is your ultimate, step-by-step guide to getting ahead of what could be the biggest investment story of our generation. By following these recommendations, you can have confidence that you’re positioned for substantial gains in the years ahead.
Lashmet just updated this report with breaking developments along with the critical steps you need to take now. These steps could more than cover the cost of accessing Dave’s research for those who act.
And that’s just the beginning. Once you’ve taken that first step, you should position yourself for potential gains of 200%, 500%, or even 1,000% in the much smaller, under-the-radar companies Dave specializes in uncovering.
These are the high-upside, venture-like opportunities at the core of Dave’s work in Stansberry Venture Technology — the kind of investments where even a small stake could turn into the biggest winner in your entire portfolio and help secure a comfortable retirement.
A Revolutionary Shift in Medicine — Unparalleled Investment Opportunity
The weight loss revolution is reshaping the medical landscape, paving the way for unimaginable high potential profits in the years ahead. And this goes far beyond the early winners of the GLP-1 boom.
Just like the early days of the tech boom, or the AI revolution in recent years, you either have to position yourself early — or you miss out the biggest gains.
Dave Lashmet And His Research
Dave is the expert behind Stansberry Venture Technology. He makes in-depth research to uncover under-the-radar technology, biotechnology, and medical companies with game-changing catalysts for rapid growth. The stocks featured in the Stansberry Venture portfolio have the potential to double or triple in value — sometimes in a short timeframe.
As one of the earliest employees at Stansberry Research, Dave has played a pivotal role in uncovering some of the biggest investment winners.
A Deep Background in Medicine, Technology, and Innovation
With a decade of experience teaching and writing about medicine and technology at major research universities, Dave has also conducted follow-up research at some of the top-tier facilities, including:
- Harvard Medical School
- Johns Hopkins University
- MIT
- Centers for Disease Control (CDC)
Beyond his research and academic work, Dave is an inventor with three issued U.S. patents in high-tech hardware and software, as well as a co-inventor on three additional patent applications currently under review by the U.S. Patent and Trademark Office.
His expertise and deep understanding of cutting-edge innovations make Stansberry Venture Technology one of the most powerful and exclusive research services available these days.
Dave’s Biotech Research
Dave has spent the past two decades researching breakthrough drugs that have the potential to revolutionize the treatment of the world’s most devastating diseases—or even eliminate them entirely. We’re talking about: Alzheimer’s, Liver disease, Chronic heart conditions.
And now, he’s recommending four additional opportunities tied to this transformation. Each with the potential for massive, fast-moving gains. In some cases, the upside is expected to reach 1,000%.
These are situations where new drug data, regulatory approvals, major cash infusions, or outright buyouts by big pharma could send stocks soaring by hundreds of percent overnight.
Getting a copy of Dave’s recently revised report, “What’s Next After GLP-1: The Innovations with Upside as High as 1,000%”, is the only way to gain access to these ideas.
Four of the greatest, early-stage companies that Dave discovered are detailed in this report. I won’t be surprised if at least one of them could cover your Stansberry Venture Technology subscription multiple times over the course of the following year.
Keep in mind that as a Stansberry Venture Technology subscriber you will keep getting Dave’s ideas in the months and years ahead. Here’s more about this membership.
Stansberry Venture Technology – How To Unlock Massive Gains with a Venture Capital Approach
As the name suggests, Stansberry Venture Technology is designed to help readers achieve extraordinary returns using a venture capital like investing approach.
Unlike investing in the private market that often require massive fees and long lock-up periods. This strategy allows investors to build a portfolio of early-stage companies with breakthrough innovations.
It’s a bold and ambitious approach where just one or two big winners could generate life-changing wealth.
At its core, Stansberry Venture Technology follows a venture capital-style philosophy: getting in early on groundbreaking technologies with the potential for 5x, 10x, or even higher returns.
This strategy isn’t limited to a single sector. In the past years Dave has been recommending early investments in AI, consumer technology, next-generation defense systems, etc. But one of the biggest focuses has always been breakthrough biotechnology, pharmaceuticals, and medical technologies. Fields where early-stage investments in research can turn into multi-billion-dollar products, and stocks can surge from just a few dollars per share to hundreds of dollars.
Biotechnology investments are speculative. However, this type of investment allows even a small number of winners to “pay for” any losses numerous times over.
Exclusive Access To Stansberry Venture Technology at an Unprecedented Price
Stansberry Venture Technology is premier research service, standing apart from everything else published by Stansberry. They rarely promote this service—let alone offer discounts.
A single year of access typically costs $5,500 — a modest price for research of this caliber.
Dave’s strategy mirrors a top-tier venture capital fund, which would usually require a $100,000+ minimum investment, lock up capital for years, and charge steep management fees.
In just the past few years, his recommendations have delivered returns of 1,139%… 691%… 1,466%… and many more exceeding 100%. That’s why they almost never discount this service.
However, this offer includes lowest price you’ll ever see offered. Use this link to join for just $2,000. That’s more than 60% off the usual price. Joining through this special offer you can actually keep this discount for as long as you choose to remain a subscriber.
What Is Included with This Offer?
When you become a member, you will receive:
- 12 months of Dave’s Stansberry Venture Technology research issues.
- Urgent “buy” and “sell” updates from Dave and his team between issues.
- SPECIAL REPORT #1: How to Profit – and Keep Profiting – From the GLP-1 Revolution. Your step-by-step manual for understanding the GLP-1 revolution and making money, including the precise steps you need to take right now to avoid missing out on the largest profits as the pill form of these medications develops.
- SPECIAL REPORT #2: What’s Next After GLP-1: The Innovations with Upside as High as 1,000%. You’ll get FOUR of Dave’s very best ideas with 200% to 1,000% upside potential.
- SPECIAL BONUS ($2,500 VALUE): TWO must-see video presentations from 2024 Alliance conference featuring nine different actionable ideas from Dave. Inside you’ll also find top 2025 stock picks from several other analysts and editors.
- Full archive of every issue and special report they’ve ever published.
- The Stansberry Venture Technology Handbook. It explains everything you need to know about Dave’s unique approach to the market.
- Dave’s entire portfolio.
Refunds & Returns Policy
This offer does not provide cash refunds due to the nature of this extremely specialized research. However, you can review everything over the next 30 days. If you are not happy with the service, contact Stansberry Research for a refund in a form of Stansberry Credit that could be applied to any other of their products.
You’ll be able to keep the reports and research you’ve already received.
Is Stansberry Venture Technology Right For Me?
Instead of suggesting a single large investment, Stansberry Venture Technology typically suggests numerous small bets spread among a dozen or more small, publicly traded companies with innovative products that have the potential to revolutionize whole sectors. With this approach they aim to potentially return five to 10 times your money.
This model portfolio’s stocks are volatile. However, their moves can be bigger than you could ever think if you can tolerate a few setbacks along the road.
They usually hold approximately 15-25 positions. And their portfolio is considered very speculative.
On the other side, the recommended capital to get started is around $50,000. They do not put on short trades and the typical holding period is 12 months to 3 years, often longer.
If this does not look like a service for your needs, look into Power Gauge Investor and Marc Chaikin’s Top 10 stocks to buy in 2025 here.
